British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- PMID: 39432739
- DOI: 10.1093/bjd/ljae385
British Association of Dermatologists living guideline for managing people with alopecia areata 2024
Plain language summary
Alopecia areata (AA) is a long-term condition that can occur in both children and adults. AA can appear as patches of baldness on the scalp. Sometimes, nail growth is also affected. Hair on other parts of the body may also fall out, such as the beard, eyebrows and eyelashes. Total loss of scalp hair is called alopecia totalis (AT). Complete loss of scalp, facial and body hair is called alopecia universalis (AU). The British Association of Dermatologists gathered a group of experts in managing people of all ages with AA. The group consisted of 11 dermatologists, 1 psychologist, 2 people with AA and a team with expertise in preparing guidelines. This group of experts reviewed relevant studies published until 19 October 2023. Using the evidence, the group produced recommendations using rigorous standards for guideline development. The guideline development group produced 49 recommendations for management of people with AA. They also made 7 recommendations for future research and suggested 11 audit points for hospitals. Based on the guideline, the group prepared an updated patient information leaflet. The leaflet is available on the British Association of Dermatologists’ website (https://www.skinhealthinfo.org.uk/condition/alopecia-areata).
Conflict of interest statement
Conflicts of interest: The GDG adhered to the BAD’s policy for declaration of interests for guideline authors. Further details may be requested by contacting guidelines@bad.org.uk. The following interests were declared over the duration of the guideline development: MJH (1) consultancy regarding UK’s treatment landscape for AA, fees from Pfizer and Lilly awarded to the NHS Trust (specific); (2) editorials pertaining to baricitinib phase III studies (specific); (3) contributed to BAD’s feedback on baricitinib and ritlecitinib for NICE’s appraisal (specific); (4) expert member of NICE baricitinib panel (specific); (5) principal investigator of a clinical trial pertaining to AA funded by Soterios/Manentia (specific); (6) principal investigator/national chief investigator of a trial funded by AbbVie (specific). LA (1) speaker fees from Pfizer, L’Oreal and Medthority US (specific); (2) subinvestigator in Pfizer-sponsored research (specific); (3) consultancy for AbbVie (AA related) and L’Oreal (nonspecific). PF (1) sponsorship from AbbVie to attend the American Academy of Dermatology Annual Meetings in Washington (2019) and Denver (2020) (nonspecific); (2) member of advisory boards for Eli Lilly and Pfizer (specific); (3) investigator for ritlecitinib (Pfizer) (specific); (4) consultant to Eli Lilly and Pfizer, regarding baricitinib and ritlecitinib, respectively (specific). GH (1) chairperson for Celgene regarding apremilast (Otezla) for the management of psoriasis and psoriatic arthritis (nonspecific); (2) sponsorship from Sanofi Genzyme to attend BAD’s annual meeting (nonspecific). SH (1) detains investments managed by investment trusts (nonspecific); (2) consultancy work for Pfizer UK (specific); (3) principal investigator for a clinical trial (ritlecitinib) funded by Pfizer (specific); (4) providing advice to a drug company on an epidemiological study on AA (specific); (5) NHS Greater Glasgow and Clyde Board has undertaken commercial clinical trials for Pfizer and Manentia and Soterios (specific); (6) coauthor on a poster presenting data from a clinical trial of a treatment for AA, presented at an international academic meeting (specific); (7) submitted evidence to NICE and SMC regarding the management of AA and the role of JAK inhibitors in this condition (specific). AJ (1) employee, Alopecia UK (specific). VMLJ (1) UK representative for Pantene Hair Research Institute (nonspecific); (2) presentations for Procter and Gamble relating to cosmetic hair products (nonspecific); (3) advisor to Soterios Ltd regarding trial of reformulated dithranol in AA (specific); (4) member of an advisory board for Pfizer regarding AA and patient pathways (specific). AEM (1) team funding received from UK Dermatology Clinical Trials Network for research into outcomes for AA (specific); (2) NIHR Eastern Dermatology Specialty Lead UK Dermatology Clinical Trials Network steering group member (specific); (3) coauthor on epidemiological research for AA with Pfizer (specific); (4) local principal investigator for a future commercial study from NIHR portfolio led by Manentia (specific); (5) local principal investigator on commercial study for topical agent in AA (specific); (6) commercial NIHR Clinical Research Network (specific); (7) NIHR Clinical Research Network Eastern Specialty lead (specific). AGM (1) coauthor of AA guidance for Up-to-Date (specific); (2) chief investigator for a clinical trial of a new topical treatment for AA, funded by Manentia (specific); (3) consultant for Pfizer (specific). ART (1) research funding from Alopecia UK (specific); (2) prior member of Alopecia UK research board; (3) consultancy and research work relating to psychosocial aspects of skin disease with pharmaceutical companies including Pfizer, UCB, Sanofi and Incyte (specific and nonspecific); (4) trustee for the charity Changing Faces (nonspecific); (5) British Psychological Society’s representative to the Scar Free Foundation (nonspecific); (6) member of the scientific board for the Vitiligo Society (nonspecific). AA, AK, AN, AT, MH, LM, MFMM and AMC have no conflicts of interest to declare.
LinkOut - more resources
Full Text Sources
